Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / EFEMP1



This biomarker is also known as:
  • FBNL,
  • Fibrillin-like protein,
  • DHRD,
  • Fibulin-3,
  • Extracellular protein S1-5,
  • fibulin 3,
  • EGF containing fibulin-like extracellular matrix protein 1,
  • FBLN3,
  • S1-5,
  • MTLV,

View in BioMuta


EFEMP1, also known as fibulin-3, binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. It may play a role in cell adhesion and migration, and may function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth. EFEMP1 is up-regulated in malignant gliomas and may play a role in the agressive nature of these tumors by increasing glioma cell adhesiveness and invasive properties.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Inactivation of EFEMP1 due to DNA hypermethylation has been seen in lung, prostate, colorectal, breast, nasopharyngeal, and hepatocellular cancers. EFEMP1 has been shown to be up-regulated in pancreatic adenocarcinoma metastases and possibly glioblastomas.

Performance Comment

EFEMP1 (fibulin-3) levels may be helpful in the diagnosis and prognosis of pleural mesothelioma. Plasma fibulin-3 levels have been shown to differentiate healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions.



Phase: One
QA State: Under Review


A single study of differences in gene expression between ovarian or primary peritoneal serous carcinomas and diffuse malignant peritoneal mesothelioma showed that EFEMP1 was overexpressed in all the mesotheliomas but in none of the ovarian or serous carcinomas.

Performance Comment

No additional ovarian data available.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.